• 2026.11.23 (Mon)
  • All articles
  • LOGIN
  • JOIN
Global Economic Times
한인동포뉴스(상단)
  • Synthesis
  • World
  • Business
  • Industry
  • ICT
  • Distribution Economy
  • Well+Being
    • Pet Life
    • Halal Horizon
  • Travel
  • Eco-News
  • Education
  • Korean Wave News
  • Opinion
  • Arts&Culture
  • Sports
  • People & Life
    • International Student Report
    • With Ambassador
  • Column
    • Cho Kijo Column
    • Cherry Garden Story
    • Ko Yong-chul Column
    • Kim Bong-seon's Photo Column
    • Kim Seul-Ong Column
    • Lee Yeon-sil Column
    • Professor Lee Soo-young’s Life Essays
  • Photo News
  • New Book Guide
MENU
 
Home > Industry

Rznomics Nears Key Milestone in $1.33B Eli Lilly Partnership Amid Biotech Sector Caution

Kim Sungmoon Reporter / Updated : 2026-11-23 08:08:47
  • -
  • +
  • Print

SEOUL — South Korean biotech firm Rznomics is approaching a pivotal moment in its partnership with pharmaceutical giant Eli Lilly, as it prepares to finalize its first drug candidate under a deal valued at up to $1.334 billion (1.9 trillion KRW). While the company anticipates converting this milestone into a formal license agreement by year-end, recent terminations of other Eli Lilly collaborations have cast a shadow of caution over the market.

Signed in May of last year, the multi-target agreement tasks Rznomics with utilizing its proprietary RNA trans-splicing ribozyme platform to identify drug candidates for targets specified by Eli Lilly. Under the arrangement, Lilly retains the option to take over preclinical, clinical, and commercial development. The deal structure allows Rznomics to receive upfront fees and milestones per target, with room to expand the partnership's scope as new targets are added.

Currently, the two companies are focusing on a therapy for hereditary hearing loss. According to Rznomics, the program has reached the final candidate selection phase, bolstered by regular consultations with Lilly’s research team. Financially, the collaboration has already outpaced early expectations; Rznomics collected four research payments from Lilly this year, bringing its cumulative third-quarter revenue to 1.6 billion KRW—surpassing its pre-IPO annual projection of 950 million KRW.

To deepen ties with its U.S. partner, Rznomics plans to open a research facility at Lilly Gateway Labs in San Diego by early next year, following a lease agreement signed in August. The company, which held 38.6 billion KRW in cash reserves at the end of Q3, is also considering additional fundraising to support ongoing R&D recruitment.

Despite steady operational progress, investors remain wary, reflected in Rznomics' stock price. After peaking at 122,625 KRW in March following its December IPO, shares have tumbled over 80%, trading at 21,250 KRW on the 19th even after a brief boost from its inclusion in the KOSDAQ 150 index.

Market skepticism stems largely from Eli Lilly’s recent string of scrapped partnerships:

Peptron: Earlier last month, Lilly concluded a two-year evaluation of South Korean firm Peptron’s long-acting drug delivery technology without moving forward to a commercial contract, triggering a sharp sell-off in Peptron shares.
Foghorn Therapeutics: In the same month, Lilly and U.S.-based Foghorn Therapeutics terminated their broader oncology collaboration after disappointing Phase 1 clinical data for their lung cancer candidate, FHD-909, forcing Foghorn to cut roughly 40% of its staff.

Rznomics maintains confidence in its platform's viability, pointing to clean safety profiles in ongoing Phase 1/2a trials for its lead internal asset, RZ-001, which targets glioblastoma and liver cancer. Beyond the Lilly deal, the company is actively pursuing global partnering opportunities and Material Transfer Agreements (MTAs) for its broader pipeline—including Alzheimer's candidate RZ-003 and retinitis pigmentosa therapy RZ-004—though it has yet to finalize any standalone intellectual property (IP) licensing deals from its portfolio of 36 registered patents.

[Copyright (c) Global Economic Times. All Rights Reserved.]

  • #Cherry Garden
  • #HalalFood
  • #Halal
  • #Petlife
  • #Halalhorizone
  • #Hormuz Impasse
  • #Joseon
  • #globaleconomictimes
  • #micore
Kim Sungmoon Reporter
Kim Sungmoon Reporter

Popular articles

  • Hanmi Pharmaceutical Confirms 'Zantrutide' as Official Name for Next-Generation Obesity Treatment

  • 30-Year Senior-Junior Duos to In-House Couples: Building AI Services All Night Without Knowing How to Code

  • NICE Acquires Additional Shares of Subsidiary NICE Property Worth 51.4 Billion Won

I like it
Share
  • Facebook
  • X
  • Kakaotalk
  • LINE
  • BAND
  • NAVER
  • https://globaleconomictimes.kr/article/1065568031497019 Copy URL copied.
Comments >

Comments 0

Weekly Hot Issue

  • South Korean Tea Maker Herb & Tea Expands Global Footprint to Nine Countries with Local Produce
  • Timor-Leste Closes Schools Amid Wildfire Smoke; Climate Crisis Halts Early Childhood Learning
  • Incheon Misses Annual Carbon Reduction Target, Prompting Calls for Industrial Cooperation
  • South Korean Court Ruling on Bird Strike Risks Threatens Nationwide Airport Expansion Plans
  • Beyond Tangerines: Warming Climate Transforms Jeju Island into a Hub for Exotic Tropical Crops
  • Washington Weighs Section 301 Trade Probe Over Digital Regulations in South Korea, EU, and Australia

Most Viewed

1
South Korea and Ethiopia Sign Trilateral MOU to Introduce Liquid-Based Cytology (LBC) Technology for Cervical Cancer Diagnosis
2
South Korean Burger Chain Lotteria Expands Singapore Footprint with Halal Certification and New Teriyaki Lineup
3
AI Semiconductor Stocks Plummet: Philadelphia Index Drops 5.28% and Micron Plunges 7.59% Amid Executive Shakeup and Export Restrictions
4
"Stay Out, Get Paid, or Have Police Stay With You": Shenzhen Imposes Strict Security Ahead of APEC Summit
5
AI Music Tops Melon Chart: Is the K-Pop Production Formula Changing?
체리가든 스토리
nutri huevos
로타리
동포저널

Hot Issue

Surge in Chinese-Built EVs Pushes South Korea’s Auto Trade Deficit with China to Record $4.23 Billion

South Korean Tea Maker Herb & Tea Expands Global Footprint to Nine Countries with Local Produce

Urban Sanctuary on Namsan: Banyan Tree Club & Spa Seoul Redefines the Luxury 'K-Staycation'

Fashion Runway Show 2026

Let’s recycle the old blankets in Jeju Island’s closet instead of incinerating them.

Global Economic Times
korocamia@naver.com
CEO : LEE YEON-SIL
Publisher & Editor : KO YONG-CHUL
Registration number : Seoul, A55681
Registration Date : 2024-10-24
Youth Protection Manager: KO YONG-CHUL
Singapore Headquarters
5A Woodlands Road #11-34 The Tennery. S'677728
Korean Branch
Phone : +82(0)10 4724 5264
#304, 6 Nonhyeon-ro 111-gil, Gangnam-gu, Seoul
Copyright © Global Economic Times All Rights Reserved
  • News K
  • 반달곰 프로젝트
  • 광고문의
Search
Category
  • All articles
  • Synthesis
  • World
  • Business
  • Industry
  • ICT
  • Distribution Economy
  • Well+Being 
    • 전체
    • Pet Life
    • Halal Horizon
  • Travel
  • Eco-News
  • Education
  • Korean Wave News
  • Opinion
  • Arts&Culture
  • Sports
  • People & Life 
    • 전체
    • International Student Report
    • With Ambassador
  • Column 
    • 전체
    • Cho Kijo Column
    • Cherry Garden Story
    • Ko Yong-chul Column
    • Kim Bong-seon's Photo Column
    • Kim Seul-Ong Column
    • Lee Yeon-sil Column
    • Professor Lee Soo-young’s Life Essays
  • Photo News
  • New Book Guide
  • Overseas Koreans
  • Multicultural News